WaveMan
WaveMan · Company
NMRA · Neumora Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NMRA Neumora Therapeutics (NMRA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001885522
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter
Conversions, 180 days
16
Codes C/M, not in net · $302.3K priced

What the filings say about NMRA

Insiders, 180 days
-$701.6K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$701.6K
5 notices

Neumora Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Neumora Therapeutics, Inc. insiders sold a net $701.6K of stock across 76 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Aurora Daljit Singh
See Remarks
SELL
2026-08-21 SEC
20,553
$32.8K
-74.2%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Aug 20, 2026.
  • The trade is 42.2% of the 48,750 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Aurora Daljit Singh sold about $32.8K of NMRA on Aug 21, 2026; 64 funds added in the latest 13F quarter.
Aurora Daljit Singh
See Remarks
SELL
2026-08-21 SEC
21,055
$33.6K
-74.2%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Aug 20, 2026.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Aurora Daljit Singh sold about $33.6K of NMRA on Aug 21, 2026; 64 funds added in the latest 13F quarter.
Aurora Daljit Singh
See Remarks
SELL
2026-08-21 SECtraded 2026-08-20
67,741
$102.6K
-74.2%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Aug 19, 2026.
  • The trade is 139.0% of the 48,750 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Aurora Daljit Singh sold about $102.6K of NMRA on Aug 20, 2026; 64 funds added in the latest 13F quarter.
Aurora Daljit Singh
See Remarks
SELL
2026-08-21 SECtraded 2026-08-20
66,711
$101.0K
-74.2%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Aug 19, 2026.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Aurora Daljit Singh sold about $101.0K of NMRA on Aug 20, 2026; 64 funds added in the latest 13F quarter.
Aurora Daljit Singh
See Remarks
SELL
2026-08-19 SEC
31,000
$51.0K
-74.1%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 18, 2026.
  • The trade is 63.6% of the 48,750 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Aurora Daljit Singh sold about $51.0K of NMRA on Aug 19, 2026; 64 funds added in the latest 13F quarter.
76 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 71 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$701.6K over 180 days
-$701.6K over 90 days
below 59% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
64 funds bought in last quarter
more than 53% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.8% of the float short (float per yahoo 2026-10-27) · 2.3 days to cover · settled 2026-10-15
below 60% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NMRA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-83.0%12M
-85%-38%+9%+55%2025-102025-122026-022026-042026-062026-082026-10 2025-10-27 · Burow Kristina bought $5.0M2025-10-27 · ARCH Venture Partners XII, LLC bought $5.0M2025-10-27 · ARCH Venture Partners VIII, LLC bought $5.0M2025-11-11 · Aurora Daljit Singh sold $307.4K2026-08-20 · Aurora Daljit Singh sold $102.6K2026-08-20 · Aurora Daljit Singh sold $101.0K2026-08-17 · Aurora Daljit Singh sold $86.8K2026-08-17 · Aurora Daljit Singh sold $82.8K2026-08-18 · Aurora Daljit Singh sold $55.5K2026-08-18 · Aurora Daljit Singh sold $54.1K2026-08-19 · Aurora Daljit Singh sold $51.0K2026-08-19 · Aurora Daljit Singh sold $50.9K2026-08-17 · Aurora Daljit Singh sold $50.5K2026-02-17 · BERNS PAUL L sold $34.5K2026-08-21 · Aurora Daljit Singh sold $33.6K2026-08-21 · Aurora Daljit Singh sold $32.8K2026-02-17 · Aurora Daljit Singh sold $21.9K2026-02-17 · Pinto Joshua sold $21.1K2026-02-17 · Milligan Michael Lee sold $5.1K2026-08-21 · Aurora Daljit Singh filed to sell $66.4K2026-08-20 · Aurora Daljit Singh filed to sell $203.6K2026-08-19 · Aurora Daljit Singh filed to sell $101.9K2026-08-18 · Aurora Daljit Singh filed to sell $109.6K2026-08-17 · Aurora Daljit Singh filed to sell $220.1K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NMRA: institutional holders (13F)

13F holdings, latest reported quarter
Siren, L.L.C.
8,497,822 sh
$14.4M
BlackRock, Inc.
7,791,869 sh
$13.2M
SOFTBANK GROUP CORP.
6,090,301 sh
$10.4M
VANGUARD CAPITAL MANAGEMENT LLC
4,669,585 sh
$7.9M
MIC Capital Management UK LLP
4,460,700 sh
$7.6M

Congress trades in NMRA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NMRA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Aurora Daljit Singh
Filed 2026-08-21
$66.4K
Aurora Daljit Singh
Filed 2026-08-20
$203.6K
Aurora Daljit Singh
Filed 2026-08-19
$101.9K
Aurora Daljit Singh
Filed 2026-08-18
$109.6K
Aurora Daljit Singh
Filed 2026-08-17
$220.1K

NMRA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$382.5K position · as of 2026-06-30
0.3%
iShares Micro-Cap ETF
$585.5K position · as of 2026-06-30
0.0%
Invesco Nasdaq Biotechnology ETF
$16.3K position · as of 2026-05-31
0.0%
1290 VT Micro Cap Portfolio
$39.3K position · as of 2026-06-30
0.0%
ProShares Ultra Nasdaq Biotechnology
$11.4K position · as of 2026-05-31
0.0%
Goldman Sachs Small Cap Growth Insights Fund
$36.3K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
0 active
4
Phase 3
0 active
What changed recently
Study to Assess the Safety and Effectiveness of NMRA-335140-501
2026-09-15 · Active Not Recruiting → Terminated · NMRA-335140 did not achieve the primary endpoint across three randomized controlled trials. Program discontinued due to lack of efficacy in MDD.
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $701.6K sold by insiders over 180 days, 64 funds added last quarter, $701.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NMRA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$180.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
2.54x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-1.60x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+229.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+149.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-140.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$69.9M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-244.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$241.2M-$263.5M-$252.1M-$135.9M
Net income$236.9M$243.8M-$235.9M-$130.9M
EPS (diluted)-1.45-1.53-3.63-4.81
Operating cash flow-$206.4M-$182.9M-$163.3M-$114.9M
Cash$182.5M$142.1M$374.0M$240.9M
Long-term debt$54.5M$0n/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

NMRA Stock Sonar score 5/7 axes

Find similar shapesCompare

NMRA ranks highest on profitability (72nd percentile) and risk and compliance (59th), and lowest on insider conviction (19th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
72
Inputs
  • Return on equity+229.7% · 99 pct, sector of 545
  • Return on assets+149.6% · 99 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-140.8% · 18 pct, sector of 576
Financial health
27
Inputs
  • Debt to equity2.54x · 7 pct, sector of 352
  • Cash flow to debt-1.60x · 46 pct, sector of 371
Insider conviction
19
Inputs
  • Net Form 4 buying (codes P and S), 180d-$702K · 38 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
53
Inputs
  • Funds adding, latest quarter64 · 53 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
59
Inputs
  • Short interest, % of float+4.8% · 59 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NMRA filings, in plain words

Are Neumora Therapeutics insiders buying or selling NMRA?

In the 180 days to 2026-10-28, Neumora Therapeutics insiders were net sellers, a net $701.6K across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of NMRA?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $701.6K of stock; the latest, by Aurora Daljit Singh, was filed 2026-08-21.

Read the full summary

In the 180 days to 2026-10-28, Neumora Therapeutics insiders were net sellers of NMRA, a net $701.6K across purchases and sales reported on Form 4 by 1 seller. None of the 11 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $701.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies